Golexanolone, a GABAA receptor-modulating steroid antagonist, improves neuroinflammation, fatigue, anxiety, depression, and some cognitive and motor alterations in a rat model of Parkinson's disease
Yaiza Mª Arenas Ortiz, Paula Izquierdo-Altarejos, Mar Martinez-García, Gergana Mincheva, Magnus Doverskog, Thomas P. Blackburn, Marta Llansola, Vicente Felipo · FENS Forum 2024
Parkinson’s disease (PD) affects more than 6 million people worldwide, and will affect more in coming decades. There are no drugs available for PD that alter progression of disease. Current symptomatic treatments provide limited relief and have side effects. Enhanced GABAergic neurotransmission contributes to Parkinson’s disease (PD) pathogenesis and to some motor and non-motor symptoms. In animal models, GABA levels are increased in substantia nigra pars compacta, leading to reduced expression of tyrosine hydroxylase (TH) in neurons which contributes to the behavioural deficits. The aim was t
ePoster · Neuroscience